In this interview, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, MO, US) discusses the outcomes of the Dare-19 Trial, which aimed to study the effects of dapagliflozin in COVID-19 patients with risk factors for complications.

Questions:
What prompted you to conduct the DARE-19 Trial?
What was the design, patient population and endpoints?
What are your key findings?
What conclusion can be made?
What are the impliactions beyond COVID-19?
How should these influence practice?
+ What are the take-home messages?

Recorded remotely from Kansas City, 2021.

Editor: Mirjam Boros